Ironwood Pharmaceuticals Share Price Today
(NASDAQ: IRWD)

Name: Ironwood Pharmaceuticals Share Price Today (NASDAQ: IRWD) - Ironwood Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Ironwood Pharmaceuticals share price is $1.54 & ₹133.93 as on 6 Mar 2025, 2.30 'hrs' IST

$1.54

▲

0.05

(3.36%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Ironwood Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Ironwood Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ironwood Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Ironwood Pharmaceuticals share price movements

Today's Low: $1.45
Today's High: $1.55
$1.54
5.84%
Downside
Day's Volatility :6.45%
Upside
0.65%
52 Weeks Low: $1.48
52 Weeks High: $9.55
$1.54
3.9%
Downside
52 Weeks Volatility :84.5%
Upside
83.87%

Ironwood Pharmaceuticals (IRWD) Returns

Period	Ironwood Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-55.39%	2.1%	0.0%
6 Months	-68.03%	-4.1%	0.0%
1 Year	-82.71%	2.2%	0.0%
3 Years	-87.05%	11.8%	-11.6%

Ironwood Pharmaceuticals (IRWD) Key Statistics

in dollars & INR

Previous Close	$1.49
Open	$1.48
Today's High	$1.55
Today's Low	$1.45
Market Capitalization	$243.2M
Today's Volume	$959.8K
52 Week High	$9.55
52 Week Low	$1.45
Revenue TTM	$351.4M
EBITDA	$99.5M
Earnings Per Share (EPS)	$0.01
PE Ratio	152.0
Profit Margin	0.52%
Quarterly Earnings Growth YOY	-0.77%
Return On Equity TTM	-574.72%

How to invest in Ironwood Pharmaceuticals Stock (IRWD) from India?

It is very easy for Indian residents to invest directly in Ironwood Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ironwood Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ironwood Pharmaceuticals or IRWD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ironwood Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ironwood Pharmaceuticals shares which would translate to 0.565 fractional shares of Ironwood Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ironwood Pharmaceuticals, in just a few clicks!

Returns in Ironwood Pharmaceuticals (IRWD) for Indian investors in Rupees

The Ironwood Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Ironwood Pharmaceuticals investment value today

Current value as on today

₹22,828

Returns

₹77,172

(-77.17%)

Returns from Ironwood Pharmaceuticals Stock

₹82,135 (-82.13%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Ironwood Pharmaceuticals (IRWD)

-11.94%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Investment in Ironwood Pharmaceuticals Shares from India has dropped by -11.94% over the past 30 days, indicating reduced transactional activity.

77%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Ironwood Pharmaceuticals Stock from India on INDmoney has increased by 77% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ironwood Pharmaceuticals

BlackRock Inc
14.40%
Vanguard Group Inc
12.21%
Sarissa Capital Management LP
10.24%
Pacer Advisors, INC.
7.33%
Armistice Capital, LLC
5.92%
Renaissance Technologies Corp
5.67%

Analyst Recommendation on Ironwood Pharmaceuticals

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Ironwood Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ironwood Pharmaceuticals Stock (IRWD)

What analysts predicted

Upside of 462.77%

Target:

$8.67

Current:

$1.54

Insights on Ironwood Pharmaceuticals Stock (Ticker Symbol: IRWD)

Price Movement
In the last 3 months, IRWD stock has moved down by -55.4%
Decreasing Revenue
Revenue is down for the last 3 quarters, 94.39M → 90.54M (in $), with an average decrease of 2.1% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -4.16M → 46.97M (in $), with an average increase of 173.5% per quarter
IRWD vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 97.0% return, outperforming this stock by 181.0%
IRWD vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 138.2% return, outperforming this stock by 224.9%
Price to Sales
ForIRWD every $1 of sales, investors are willing to pay $0.8, whereas for Intra-cellular Therapies, Inc., the investors are paying $19.9 for every $1 of sales.

IRWD Ironwood Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$428.4M	↑ 23.59%
Net Income	$-15.3M	↓ 94.58%
Net Profit Margin	-3.57%	↑ 77.89%

	FY20	Y/Y Change
Revenue	$389.5M	↓ 9.08%
Net Income	$106.2M	↓ 793.33%
Net Profit Margin	27.26%	↑ 30.83%

	FY21	Y/Y Change
Revenue	$413.8M	↑ 6.22%
Net Income	$528.4M	↑ 397.71%
Net Profit Margin	127.72%	↑ 100.46%

	FY22	Y/Y Change
Revenue	$410.6M	↓ 0.76%
Net Income	$175.1M	↓ 66.87%
Net Profit Margin	42.64%	↓ 85.08%

	FY23	Y/Y Change
Revenue	$442.7M	↑ 7.83%
Net Income	$-1.0B	↓ 672.5%
Net Profit Margin	-226.37%	↓ 269.01%

	FY24	Y/Y Change
Revenue	$351.4M	↓ 20.63%
Net Income	$130.8M	↓ 113.05%
Net Profit Margin	37.21%	↑ 263.58%

	Q3 FY23	Q/Q Change
Revenue	$113.7M	↑ 5.92%
Net Income	$15.3M	↓ 101.44%
Net Profit Margin	13.47%	↑ 1002.64%

	Q4 FY23	Q/Q Change
Revenue	$117.6M	↑ 3.35%
Net Income	$-1.1M	↓ 107.09%
Net Profit Margin	-0.92%	↓ 14.39%

	Q1 FY24	Q/Q Change
Revenue	$74.9M	↓ 36.3%
Net Income	$-4.2M	↑ 282.89%
Net Profit Margin	-5.56%	↓ 4.64%

	Q2 FY24	Q/Q Change
Revenue	$94.4M	↑ 26.07%
Net Income	$-860.0K	↓ 79.34%
Net Profit Margin	-0.91%	↑ 4.65%

	Q3 FY24	Q/Q Change
Revenue	$91.6M	↓ 2.97%
Net Income	$31.1M	↓ 3715.35%
Net Profit Margin	33.95%	↑ 34.86%

	Q4 FY24	Q/Q Change
Revenue	$90.5M	↓ 1.14%
Net Income	$47.0M	↑ 51.07%
Net Profit Margin	51.88%	↑ 17.93%

	FY19	Y/Y Change
Profit	$404.5M	↑ 28.88%

	FY20	Y/Y Change
Profit	$386.4M	↓ 4.49%

	FY21	Y/Y Change
Profit	$412.2M	↑ 6.69%

	FY22	Y/Y Change
Profit	$409.2M	↓ 0.74%

	FY23	Y/Y Change
Profit	$338.0M	↓ 17.41%

	FY24	Y/Y Change
Profit	$351.4M	↑ 3.98%

	Q3 FY23	Q/Q Change
Profit	$113.2M	↑ 5.71%

	Q4 FY23	Q/Q Change
Profit	$117.0M	↑ 3.36%

	Q1 FY24	Q/Q Change
Profit	$74.4M	↓ 36.46%

	Q2 FY24	Q/Q Change
Profit	$93.9M	↑ 26.26%

	Q3 FY24	Q/Q Change
Profit	$91.6M	↓ 2.45%

	Q4 FY24	Q/Q Change
Profit	$90.5M	↓ 1.14%

	FY18	Y/Y Change
Operating Cash Flow	$-70.9M	↓ 28.81%
Investing Cash Flow	$88.9M	↓ 41.33%
Financing Cash Flow	$30.1M	↑ 51.61%

	FY19	Y/Y Change
Operating Cash Flow	$10.7M	↓ 115.13%
Investing Cash Flow	$-11.1M	↓ 112.54%
Financing Cash Flow	$-1.2M	↓ 103.94%

	FY20	Y/Y Change
Operating Cash Flow	$168.8M	↑ 1474.23%
Investing Cash Flow	$-1.8M	↓ 83.47%
Financing Cash Flow	$18.5M	↓ 1665.06%

	FY21	Y/Y Change
Operating Cash Flow	$261.9M	↑ 55.12%
Investing Cash Flow	$-265.0K	↓ 85.61%
Financing Cash Flow	$-4.6M	↓ 124.53%

	FY22	Y/Y Change
Operating Cash Flow	$273.8M	↑ 4.53%
Investing Cash Flow	$-136.0K	↓ 48.68%
Financing Cash Flow	$-237.6M	↑ 5120.95%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$35.0M	↓ 56.39%
Investing Cash Flow	$-999.5M	↑ 7688300.0%
Financing Cash Flow	$399.1M	↑ 9924.39%

Ironwood Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Ironwood Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ironwood Pharmaceuticals (IRWD) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ironwood Pharmaceuticals, Inc.	-28.88%	-68.03%	-82.71%	-87.05%	-86.85%
Intra-cellular Therapies, Inc.	3.42%	81.22%	98.76%	146.55%	588.92%
Haleon Plc Spon Ads	12.55%	3.39%	28.09%	43.99%	43.99%
Zoetis Inc.	-1.19%	-8.94%	-7.43%	-9.67%	30.97%
Neurocrine Biosciences Inc.	-24.64%	-6.68%	-14.47%	28.61%	27.88%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ironwood Pharmaceuticals, Inc.	152.0	152.0	-0.26	0.17	-5.75	0.15	NA	-1.89
Intra-cellular Therapies, Inc.	NA	NA	0.0	0.13	-0.09	-0.07	NA	10.81
Haleon Plc Spon Ads	26.68	26.68	1.5	0.36	0.09	0.04	0.02	1.8
Zoetis Inc.	31.17	31.17	3.01	6.07	0.51	0.15	0.01	10.64
Neurocrine Biosciences Inc.	34.8	34.8	0.27	6.47	0.14	0.1	NA	26.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ironwood Pharmaceuticals, Inc.	Buy	$243.2M	-86.85%	152.0	0.52%
Intra-cellular Therapies, Inc.	Buy	$14.0B	588.92%	NA	-10.97%
Haleon Plc Spon Ads	Buy	$48.2B	43.99%	26.68	12.84%
Zoetis Inc.	Buy	$76.1B	30.97%	31.17	26.86%
Neurocrine Biosciences Inc.	Buy	$11.3B	27.88%	34.8	14.49%

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Organization	Ironwood Pharmaceuticals
Employees	0
CEO	Mr. Thomas A. McCourt
Industry	Health Technology

Management People of Ironwood Pharmaceuticals

Name	Title
Mr. Thomas A. McCourt	CEO & Director
Mr. John Minardo	Senior VP, Chief Legal Officer & Secretary
Dr. Michael Shetzline M.D., Ph.D.	Chief Medical Officer, Senior VP and Head of Research & Drug Development
Mr. Greg Martini	CFO & Investor Realtions
Mr. Ronald Silver	Corporate Controller & Principal Accounting Officer
Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.	VP & Global Head of Technical Operations
Mr. Mike Nanfito	Vice President of Sales & Sales Excellence
Tammi Gaskins	Senior Vice President & Chief Commercial Officer.
Mr. Matt Roache	Director of Investor Relations

Important FAQs about investing in IRWD Stock from India :

What is Ironwood Pharmaceuticals share price today?

Ironwood Pharmaceuticals share price today stands at $1.54, Open: $1.48 ; Previous Close: $1.49 ; High: $1.55 ; Low: $1.45 ; 52 Week High: $9.55 ; 52 Week Low: $1.48.

The stock opens at $1.48, after a previous close of $1.49. The stock reached a daily high of $1.55 and a low of $1.45, with a 52-week high of $9.55 and a 52-week low of $1.48.

Can Indians buy Ironwood Pharmaceuticals shares?

Yes, Indians can invest in the Ironwood Pharmaceuticals (IRWD) from India.

With INDmoney, you can buy Ironwood Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ironwood Pharmaceuticals at zero transaction cost.

How can I buy Ironwood Pharmaceuticals shares from India?

It is very easy to buy Ironwood Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ironwood Pharmaceuticals (IRWD) be purchased?

Yes, you can buy fractional shares of Ironwood Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Ironwood Pharmaceuticals stocks?

To start investing in Ironwood Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.